We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study.
- Abstract
The article discusses a study which examined whether intravenous (IV) bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), could inhibit neovessel formation after transarterial chemoembolization (TACE). The study concluded that IV bevacizumab was well tolerated in selected hepatocellular cancer (HCC) subjects undergoing TACE, and appeared to diminish neovessel formation at week 14.
- Publication
BMC Cancer, 2012, Vol 12, Issue 1, p16
- ISSN
1471-2407
- Publication type
Academic Journal
- DOI
10.1186/1471-2407-12-16